Table 3:
Characteristics of Included Studies—Mechanochemical Ablation
| Sample Size, N | CVI Severity, CEAP C Class, n (%) | Age, Mean (SD), Y | ||||||
|---|---|---|---|---|---|---|---|---|
| Author, Year | Study Design, (Country) | Vein(s) Treated, Mean Diameter, mm (± SD) | MOCA | Comparator | MOCA | Comparator | MOCA | Comparator |
| Compared With RFA and EVLA | ||||||||
| Kim et al, 201978 | Retrospective chart analysis (United States) | GSV, SSV, ASV, Giacomini, perforator, multiple segments: NR | 53a | 25b (thermal treatments combined) | C6 only | C6 only | 67.9 (11.6)c | 57.2 (13.5)c |
| Vahaaho et al, 2019, 202080,85 | RCT (Finland) | Thigh GSV MOCA 6.7 (1.6) EVLA 6.5 (1.6) RFA 6.4 (1.8) |
59 |
EVLA 34 RFA 32 |
C2: 32 (54.3) C3: 14 (23.7) C4: 13 (22.0) Missing: 0 |
EVLA C2: 20 (58.8) C3: 6 (17.6) C4:7 (20.6) Missing: 1 (2.9) RFA C2: 18 (56.2) C3: 7 (21.9) C4:7 (21.9) Missing: 0 |
50.9 (12) |
EVLA 49.5 (11.9) RFA 50.3 (13.9) |
| Vun et al, 201576 | Prospective cohort (Australia) | GSV, SSV Overall MD 9 (IQR 4–12) | 55 |
RFA 50 EVLA 40 |
Overall C2–6 | Overall MD 50 (IQR 31–82) | ||
| Compared With EVLA | ||||||||
| Mohamed et al, 202083 | RCT (United Kingdom) | GSV, SSV, AASV MOCA 6.5 (± 1.5) EVLA 6.9 (± 2.1) |
75 | 75 | C2: 28 C3: 31 C4: 35 C5: 4 C6: 1 |
C2: 20 C3: 39 C4: 33 C5: 8 C6: 0 |
53 (14) | 51 (14) |
| Compared With RFA | ||||||||
| Holewijn et al, 201979 | RCT (Netherlands) | GSV MOCA MD 6 (IQR 0.8–12) RFA 6 (IQR 1.2–14) |
105 | 104 | C2: 5.9 C3: 59.8 C4a: 31.4 C4b: 2 C5: 2 |
C2: 4.2 C3: 66.7 C4a: 22.9 C4b: 3.1 C5: 3.1 |
MD 54.9 (IQR 16.3–81.2) | MD 53.4 (IQR 22.8–77.9) |
| Moon et al, 201777 | Prospective cohort (United Kingdom) | GSV: NR | 11 | 17 | NRd | NRd | 46 (NR) | 55 (NR) |
| Lane et al, 201774; Bootun et al, 201673 | RCT (United Kingdom) | GSV, SSV MOCA MD 7 RFA MD 7 |
87 | 83 | MD 4 | MD 4 | MD 54.5 | MD 48 |
| van Eekeren et al, 201375 | Prospective comparative cohort (Netherlands) | GSV MOCA 5.7 (1.6) RFA 6.8 (2.4)e |
34 | 34 | C1: 3 C2: 47 C3: 23.5 C4: 23.5 C5–6: 3 |
C1: 0 C2: 26 C3: 30 C4: 41 C5–6: 3 |
57.2 (15.2) | 58 (17.8) |
Abbreviations: AASV, anterior accessory saphenous vein; ASV, accessory saphenous vein; CEAP, Clinical-Etiologic-Anatomic-Pathophysiologic classification; CVI, chronic venous insufficiency; EVLA, endovenous laser ablation; GSV, great saphenous vein; IQR, interquartile range; MA, meta-analysis; MD, median; MOCA, mechanochemical ablation; NR, not reported; RCT, randomized controlled trial; RFA, radiofrequency ablation; SD, standard deviation; SSV, small saphenous vein; Y, years.
Results reported for 41 in the MOCA group.78
As reported by Table 1 in Kim et al, 2019.78 Article text reports that 11 people underwent EVLA and 18 RFA.
MOCA group significantly older (P = .0003).78
Study only reports mean VCSS score of 5.5 in MOCA group, 4.9 in RFA group (P = .6262).77
Vein diameter in RFA group was statistically significantly wider (P = .03).75